TARGETING THE CHK1-STAT3-CIP2A AXIS TO TREAT GLIOBLASTOMA (GBM)
Funder
National Health and Medical Research Council
Funding Amount
$321,048.00
Summary
Glioblastoma (GBM is a high-grade brain tumour for which current treatments are inadequate. Tumour recurrence is almost inevitable and average life expectancy is measured in months. We have identified a DNA-damage signalling pathway and demonstrated that perturbation of the pathway significantly reduces tumour growth. We plan to target key proteins of the recently identified pathway and validate these findings using tumour cells directly from GBM patients and relevant animal models of human GBM.
Development Of Prognostic And Predictive Biomarkers To Aid Treatment Of Lung Cancer
Funder
National Health and Medical Research Council
Funding Amount
$188,226.00
Summary
Although a number of new therapies are emerging in the treatment of lung cancer, chemotherapy remains the backbone of treatment for most patients. Currently we are unable to predict who will benefit from chemotherapy with some patients deriving no benefit but experiencing significant toxicity. Our group has investigated a number of biomarkers and found them to predict response to chemotherapy. These markers may be used to determine patients most likely to derive benefit from chemotherapy.
Identifying Novel Genome Instability Signatures In Cancer
Funder
National Health and Medical Research Council
Funding Amount
$320,891.00
Summary
Cancer is the single biggest clinical problem facing the world. An underlying hallmark of cancer is the accumulation of errors in the genetic information of a cell which arises through genomic instability. This research project aims to investigate novel molecules identified by our screening that function in response to genomic instability in cancer. This study is expected to define roles for each molecule in the maintenance of genomic stability and predict for patient diagnosis and outcome.
Outcomes Of Treatment Decisions And Prediction Of Individual Treatment Response In Multiple Sclerosis
Funder
National Health and Medical Research Council
Funding Amount
$92,358.00
Summary
Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal of freedom from disease has become more realistic. We will use the MSBase international multiple sclerosis registry to identify optimal, individually-tailored therapeutic strategies. We will also implement volumetric magnetic resonance imaging in routine practice, thus translating a research tool into an instrument available to patients and their doctors.